Royalty Pharma (RPRX) Total Non-Current Liabilities (2019 - 2026)

Royalty Pharma has disclosed Total Non-Current Liabilities across 8 years of filings, most recently posting $9.2 billion for Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $9.2 billion, up 18.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.2 billion (up 18.31% YoY), and the FY2025 annual result was $9.3 billion, up 18.37% from the prior year.
• Total Non-Current Liabilities came in at $9.2 billion for Q1 2026 at Royalty Pharma, down from $9.3 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $9.3 billion in Q4 2025 to a low of $6.3 billion in Q3 2023.
• The 5-year median for Total Non-Current Liabilities is $7.5 billion (2023), against an average of $7.7 billion.
• Across the five-year window, Total Non-Current Liabilities slipped 13.62% in 2023 and climbed 25.15% in 2024, its largest moves.
• Royalty Pharma's Total Non-Current Liabilities stood at $7.3 billion in 2022, then decreased by 13.57% to $6.3 billion in 2023, then rose by 25.15% to $7.9 billion in 2024, then climbed by 18.37% to $9.3 billion in 2025, then declined by 1.05% to $9.2 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at $9.2 billion (Q1 2026), $9.3 billion (Q4 2025), and $9.2 billion (Q3 2025), per Business Quant data.